+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of clinical and molecular markers in advanced ovarian cancer (AOC): importance of residual (Rs) disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 Phase III Randomized Clinical Trial (RCT)



Prognostic value of clinical and molecular markers in advanced ovarian cancer (AOC): importance of residual (Rs) disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 Phase III Randomized Clinical Trial (RCT)



Journal of Clinical Oncology 23(16_suppl): 5005-5005



NlmCategory="UNASSIGNED">5005 Background: Rational selection of therapy in AOC requires molecular and prognostic profiling. We analyzed clinical (clin) and molecular (mol) markers from patients (pts) who participated in a multi-centre phase III RCT that demonstrated superiority of cisplatin (c)/paclitaxel over c/cyclophosphamide, and put these results in context of progression free survival (PFS) and overall survival (OS). EORTC 55931/NCIC OV10 was a RCT that enrolled 680 pts between 1994 and 1995, with 391 from EORTC and NCIC CTG. Paraffin fixed tumor tissue was retrospectively retrieved and analyzed from 95 pts. Demographics of pts whose tissue was available were similar to the entire randomized population. 96% of pt had stage III/IV disease and 80% had Rs disease > 1cm when they commenced chemotherapy. Mol markers analyzed were P53, BCL2, P21, Mib-1, c-Erb B2, DNA ploidy, S-phase and mitotic index. Median follow-up time was 6.4 years. Mol and clin factors were analyzed as potential prognostic factors for PFS and OS, with stratification for treatment in univariate (UV) and multivariate (MV) analyses. P53 was measured independently in Amsterdam and Toronto for the entire group, with the results blinded to the testing laboratories. The concordance between the two data sets was a measure of quality control and reproducibility. The correlation between the two laboratories for P53 status was high (Cohen's Kappa coefficient 0.8; p<0.001). UV analysis: there was significant (S) correlation between size of Rs disease and PFS (p=0.002) as well as OS (p=0.02). Stage and mitotic index were S predictors of OS (p=0.05 and 0.02), but not PFS. MV analysis: only Rs tumor mass remained S for PFS (p=0.002) and OS (p=0.02). The Hazard Ratio for patients with Rs disease > 1cm compared with <1cm was 2.4 for OS and 2.8 for PFS. Other mol and clin factors provided no additional information and were not retained in the final model. Assessment of clin and mol markers in women with AOC demonstrates that Rs tumor volume is S for predicting PFS and OS. None of the mol factors measured were independent predictors of these outcomes. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 058637685

Download citation: RISBibTeXText

PMID: 27946265


Related references

The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study Results of an EORTC - NCIC - SAKK neoadjuvant trial in patients with locally advanced breast cancer. European Journal of Cancer 35(SUPPL 4): S313, Sept, 1999

Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center. Annals of Oncology 4(4): 303-306, 1993

Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group. European Journal of Cancer 30a(1): 45-49, 1994

Radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus radiotherapy alone for newly diagnosed glioblastoma (GBM): Overall results and recursive partitioning analysis (RPA) of a phase III randomized trial of the EORTC brain tumor and radiotherapy groups and the NCIC clinical trial group. International Journal of Radiation Oncology*biology*physics 60: S162-S162, 2004

A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. Journal of Clinical Oncology 26(15_suppl): Lba5505-Lba5505, 2016

Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Research and Treatment 150(3): 605-611, 2016

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecologic Oncology 130(2): 269-274, 2013

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: An NCIC clinical trials group study (NCIC IND.116). Gynecologic Oncology 89(1): 129-133, 2003

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. Journal of Clinical Oncology 21(5): 843-850, 2003

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 116(2): 362-368, 2010

The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. British Journal of Cancer 97(3): 302-307, 2007

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer - EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group. EJC Supplements 2(3): 126, 2004

Cambridge Translational Cancer Research Ovarian Study 01 (CTCR-OV01): Expression profiling of advanced epithelial ovarian cancer (EOC) to predict chemotherapy response. A randomised phase II trial design with prospective translational endpoints. Journal of Clinical Oncology 24(18_suppl): 15018-15018, 2016

Phase II study of cystemustine in advanced head and neck cancer. A trial of the EORTC Clinical Screening Group. European Journal of Cancer. Part B, Oral Oncology 31b(2): 151-152, 1995

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Annals of Oncology 6(2): 129-132, 1995